摘要
The title compound 4-(5-(2,6-difluorophenyl)-1,3,4-oxadiazol-2-ylthio)-2-(trifluoromethyl)thieno[2,3-d]pyrimidine(C15H5F5N4OS2, Mr = 416.35) was designed and synthesized as antitumor agent, and its structure was determined by 1H NMR, 13C NMR, MS, elemental analysis and single-crystal X-ray diffraction. The crystal belongs to monoclinic system, space group P21/c with a = 9.904(2), b = 10.057(2), c = 16.595(3) ?, β = 100.000(3)°, V = 1627.9(6) ?3, Z = 4, F(000) = 832, Dc = 1.699 g/cm3, μ = 0.395 mm-1, R = 0.0468 and wR = 0.1255 for 4726 independent reflections(Rint = 0.0336) and 2847 observed ones(I > 2σ(I)). The in vitro antitumor activity of the title compound was preliminarily evaluated by the standard MTT assay.
The title compound 4-（5-（2,6-difluorophenyl）-1,3,4-oxadiazol-2-ylthio）-2-（trifluoromethyl）thieno[2,3-d]pyrimidine(C15H5F5N4OS2, Mr = 416.35) was designed and synthesized as antitumor agent, and its structure was determined by 1H NMR, 13C NMR, MS, elemental analysis and single-crystal X-ray diffraction. The crystal belongs to monoclinic system, space group P21/c with a = 9.904（2）, b = 10.057（2）, c = 16.595（3） ?, β = 100.000（3）°, V = 1627.9（6） ?3, Z = 4, F（000） = 832, Dc = 1.699 g/cm3, μ = 0.395 mm-1, R = 0.0468 and wR = 0.1255 for 4726 independent reflections(Rint = 0.0336) and 2847 observed ones（I > 2σ（I））. The in vitro antitumor activity of the title compound was preliminarily evaluated by the standard MTT assay.
作者
宋新建
李晨晨
王旭梅
孙琦
杨平
SONG Xin-Jian;LI Chen-Chen;WANG Xu-Mei;SUN Qi;YANG Ping(School of Chemical and Environmental Engineering,Hubei University for Nationalities,Enshi 445000,China;College of Chemistry and Environmental Engineering,Sichuan University of Science and Engineering,Zigong 643000,China)
基金
supported by the National Natural Science Foundation of China(No.21262012)
